JP7141129B2 - Ｃ５ａ阻害剤としての５－５融合環 - Google Patents

Ｃ５ａ阻害剤としての５－５融合環 Download PDF

Info

Publication number
JP7141129B2
JP7141129B2 JP2019565826A JP2019565826A JP7141129B2 JP 7141129 B2 JP7141129 B2 JP 7141129B2 JP 2019565826 A JP2019565826 A JP 2019565826A JP 2019565826 A JP2019565826 A JP 2019565826A JP 7141129 B2 JP7141129 B2 JP 7141129B2
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019565826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522483A (ja
JP2020522483A5 (cg-RX-API-DMAC7.html
Inventor
ファン ピンチェン
ダブリュ．ランゲ クリストファー
エム．ルイ レベッカ
マラソン ビエンカム
レディ マリ ベンカット
プンナ スリニバス
イーピン ツォン
ジャーン ペングリー
Original Assignee
ケモセントリックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス，インコーポレイティド filed Critical ケモセントリックス，インコーポレイティド
Publication of JP2020522483A publication Critical patent/JP2020522483A/ja
Publication of JP2020522483A5 publication Critical patent/JP2020522483A5/ja
Application granted granted Critical
Publication of JP7141129B2 publication Critical patent/JP7141129B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Insulating Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019565826A 2017-05-31 2018-05-29 Ｃ５ａ阻害剤としての５－５融合環 Active JP7141129B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513025P 2017-05-31 2017-05-31
US62/513,025 2017-05-31
PCT/US2018/034908 WO2018222601A1 (en) 2017-05-31 2018-05-29 5-5 FUSED RINGS AS C5a INHIBITORS

Publications (3)

Publication Number Publication Date
JP2020522483A JP2020522483A (ja) 2020-07-30
JP2020522483A5 JP2020522483A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7141129B2 true JP7141129B2 (ja) 2022-09-22

Family

ID=64455572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565826A Active JP7141129B2 (ja) 2017-05-31 2018-05-29 Ｃ５ａ阻害剤としての５－５融合環

Country Status (15)

Country Link
US (2) US10683294B2 (cg-RX-API-DMAC7.html)
EP (1) EP3630774B1 (cg-RX-API-DMAC7.html)
JP (1) JP7141129B2 (cg-RX-API-DMAC7.html)
KR (1) KR102586710B1 (cg-RX-API-DMAC7.html)
CN (1) CN111032658B (cg-RX-API-DMAC7.html)
AR (1) AR111841A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018277523B2 (cg-RX-API-DMAC7.html)
CA (1) CA3064025A1 (cg-RX-API-DMAC7.html)
ES (1) ES2934507T3 (cg-RX-API-DMAC7.html)
IL (1) IL270842B2 (cg-RX-API-DMAC7.html)
MA (1) MA48800A (cg-RX-API-DMAC7.html)
MX (1) MX391392B (cg-RX-API-DMAC7.html)
TW (1) TWI813570B (cg-RX-API-DMAC7.html)
WO (1) WO2018222601A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907755B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
KR102852027B1 (ko) 2017-12-22 2025-08-27 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 5,5-융합 고리 화합물
ES2980175T3 (es) * 2017-12-22 2024-09-30 Chemocentryx Inc Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
CN111954525B (zh) * 2018-04-02 2023-12-26 凯莫森特里克斯股份有限公司 稠合双环C5aR拮抗剂的前药
CN114206338B (zh) 2019-07-10 2025-12-12 凯莫森特里克斯股份有限公司 作为pd-l1抑制剂的二氢化茚类
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
PH12022550877A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
EP4219453A4 (en) * 2020-09-28 2024-10-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PYRAZOLE COMPOUND AND ITS PREPARATION METHOD AND ITS USE
JP2023548117A (ja) 2020-10-28 2023-11-15 ケモセントリックス， インコーポレイテッド 化膿性汗腺炎を処置する方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
JP2006524228A (ja) 2003-04-23 2006-10-26 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
JP2014521607A (ja) 2011-07-22 2014-08-28 ノバルティス アーゲー テトラヒドロピリド−ピリジンおよびテトラヒドロピリド−ピリミジン化合物およびＣ５ａ受容体モジュレーターとしてのその使用
JP2015524853A (ja) 2012-08-16 2015-08-27 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル遮断剤としてのピロロピラゾール

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP5260818B2 (ja) 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
JP4196678B2 (ja) 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
JP2006508894A (ja) 2002-03-28 2006-03-16 ニューロジェン・コーポレーション Ｃ５ａ受容体調節因子としての置換テトラヒドロイソキノリン
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
US20040014782A1 (en) 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004018460A1 (en) 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CN102131390A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
ES2980175T3 (es) 2017-12-22 2024-09-30 Chemocentryx Inc Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
KR102852027B1 (ko) 2017-12-22 2025-08-27 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 5,5-융합 고리 화합물
CN111954525B (zh) 2018-04-02 2023-12-26 凯莫森特里克斯股份有限公司 稠合双环C5aR拮抗剂的前药

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524228A (ja) 2003-04-23 2006-10-26 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
JP2014521607A (ja) 2011-07-22 2014-08-28 ノバルティス アーゲー テトラヒドロピリド−ピリジンおよびテトラヒドロピリド−ピリミジン化合物およびＣ５ａ受容体モジュレーターとしてのその使用
JP2015524853A (ja) 2012-08-16 2015-08-27 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル遮断剤としてのピロロピラゾール

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2014年，24，2053-2056

Also Published As

Publication number Publication date
CN111032658A (zh) 2020-04-17
TWI813570B (zh) 2023-09-01
JP2020522483A (ja) 2020-07-30
TW201902897A (zh) 2019-01-16
US20180346471A1 (en) 2018-12-06
AR111841A1 (es) 2019-08-21
MX391392B (es) 2025-03-21
US20210009594A1 (en) 2021-01-14
AU2018277523B2 (en) 2022-06-23
IL270842B2 (en) 2023-05-01
MX2019014292A (es) 2022-04-07
CA3064025A1 (en) 2018-12-06
ES2934507T3 (es) 2023-02-22
EP3630774A4 (en) 2020-10-07
MA48800A (fr) 2020-04-08
BR112019025230A2 (pt) 2020-06-16
CN111032658B (zh) 2022-12-20
KR20200013720A (ko) 2020-02-07
KR102586710B1 (ko) 2023-10-10
WO2018222601A1 (en) 2018-12-06
ZA201907755B (en) 2023-05-31
IL270842B1 (en) 2023-01-01
US10683294B2 (en) 2020-06-16
AU2018277523A1 (en) 2019-12-05
IL270842A (en) 2020-01-30
RU2019142985A (ru) 2021-06-30
EP3630774B1 (en) 2022-11-23
US11479553B2 (en) 2022-10-25
EP3630774A1 (en) 2020-04-08
RU2019142985A3 (cg-RX-API-DMAC7.html) 2021-09-03

Similar Documents

Publication Publication Date Title
JP7141129B2 (ja) Ｃ５ａ阻害剤としての５－５融合環
US11773091B2 (en) 6-5 fused rings as C5a inhibitors
JP7253557B2 (ja) Ｃ５ａＲ阻害剤としてのジアリール置換５，５－縮合環化合物
TWI789470B (zh) 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物
RU2780322C2 (ru) 5-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
RU2780338C2 (ru) 6-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
RU2785549C2 (ru) ДИАРИЛ-ЗАМЕЩЕННЫЕ 5,5 СОПРЯЖЕННЫЕ ЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ C5aR
HK40026719A (en) 5-5 fused rings as c5a inhibitors
HK40026719B (en) 5-5 fused rings as c5a inhibitors
BR112019025230B1 (pt) Anéis 5-5 fundidos como inibidores de c5a, seus usos e composição farmacêutica
HK40026727B (en) 6-5 fused rings as c5a inhibitors
HK40026727A (en) 6-5 fused rings as c5a inhibitors
BR112019025049B1 (pt) Compostos com anéis 6- 5 fundidos e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220902

R150 Certificate of patent or registration of utility model

Ref document number: 7141129

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150